Skip to main content

The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value?

Publication ,  Journal Article
Yancy, CW; Hernandez, AF; Bonow, RO
Published in: JAMA Cardiol
November 1, 2020

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

November 1, 2020

Volume

5

Issue

11

Start / End Page

1244

Location

United States

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Stroke Volume
  • Humans
  • Heart Failure
  • Drug Combinations
  • Cost-Benefit Analysis
  • Biphenyl Compounds
  • Aminobutyrates
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yancy, C. W., Hernandez, A. F., & Bonow, R. O. (2020). The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? JAMA Cardiol, 5(11), 1244. https://doi.org/10.1001/jamacardio.2020.3108
Yancy, Clyde W., Adrian F. Hernandez, and Robert O. Bonow. “The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value?JAMA Cardiol 5, no. 11 (November 1, 2020): 1244. https://doi.org/10.1001/jamacardio.2020.3108.
Yancy CW, Hernandez AF, Bonow RO. The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? JAMA Cardiol. 2020 Nov 1;5(11):1244.
Yancy, Clyde W., et al. “The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value?JAMA Cardiol, vol. 5, no. 11, Nov. 2020, p. 1244. Pubmed, doi:10.1001/jamacardio.2020.3108.
Yancy CW, Hernandez AF, Bonow RO. The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? JAMA Cardiol. 2020 Nov 1;5(11):1244.

Published In

JAMA Cardiol

DOI

EISSN

2380-6591

Publication Date

November 1, 2020

Volume

5

Issue

11

Start / End Page

1244

Location

United States

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Stroke Volume
  • Humans
  • Heart Failure
  • Drug Combinations
  • Cost-Benefit Analysis
  • Biphenyl Compounds
  • Aminobutyrates
  • 3201 Cardiovascular medicine and haematology